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Since its discovery in the 1970s, the mitochondrial permeability transition (MPT) has been
proposed to be a strategic regulator of cell death. Intense research efforts have focused
on elucidating the molecular components of the MPT because this knowledge may help
to better understand and treat various pathologies ranging from neurodegenerative and
cardiac diseases to cancer. In the case of cancer, several studies have revealed alterations
in the activity of the mitochondrial permeability transition pore (mPTP) and have deter-
mined its regulatory mechanism; these studies have also suggested that suppression of
the activity of the mPTP, rather than its inactivation, commonly occurs in solid neoplasms.
This review focuses on the most recent advances in understanding mPTP regulation in
cancer and highlights the ability of the mPTP to impede the mechanisms of cell death.
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INTRODUCTION
The mitochondrial permeability transition (MPT) refers to an
alteration in the permeability of the inner mitochondrial mem-
brane (IMM), which was characterized for the first time in 1979
(1). The interest in this unusual mitochondrial state increased
exponentially in the 1990s after the MPT was shown to be a
strategic regulator of cell death (2). In the earliest study on this
subject, the MPT was shown to be induced by high concentrations
of mitochondrial Ca2+ ([Ca2+]m) and to be inhibited by Mg2+
and adenosine diphosphate (ADP) (1). In a later study, oxidative
stress was also reported to induce the MPT (3). Thus, [Ca2+]m
and oxidative stress are currently known as the two stereotypical
activators of MPT. The MPT has detrimental effects not only on
Abbreviations: ANT, adenine nucleotide translocator; Bax, Bcl-2-associated protein
X; Bak, Bcl-2 homologous antagonist killer; Bcl-2, B-cell lymphoma 2; Bcl-Xl, B-cell
lymphoma-extra large; CypD, cyclophilin D; CK, creatine kinase; CsA, cyclosporine
A; ER, endoplasmic reticulum; GSK3β, glycogen synthase kinase 3 beta; HIF1α,
hypoxia-inducible factor 1 alpha; HKII, hexokinase 2; H-RAS, Harvey rat sarcoma
viral oncogene homolog; HSP60, heat shock protein 60; HSP90, heat shock pro-
tein 90; IMM, inner mitochondrial membrane; IP3R, inositol phosphate 3 receptor;
MAMs, mitochondria-associated membranes; Mcl-1, myeloid cell leukemia 1; MPT,
mitochondria permeability transition; mPTP,mitochondrial permeability transition
pore; OMM, outer mitochondrial membrane; PKC, protein kinase C; PML, promye-
locytic leukemia; PP2A, protein phosphatase 2A; PTEN, phosphatase and tensin
homolog; ROS, reactive oxygen species; SOD-2, superoxide dismutase-2; TRAP-1,
TNF receptor-associated protein-1; TRX-2, thioredoxin reductase; TSPO, transloca-
tor protein; VDAC, voltage-dependent anion channel; WNT, wingless-type MMTV
integration site family member.
mitochondria but also on the entire cell. A loss of IMM permeabil-
ity leads to rapid loss of the mitochondrial membrane potential
(∆Ψmt) and the consequent loss of adenosine triphosphate (ATP)
as well as osmotic shock to the organelle and rupture of the
outer mitochondrial membrane (OMM). The loss of ATP causes
a loss of ion homeostasis and cell integrity, which finally results in
necrosis (4).
Interestingly, these acute phenomena are efficiently prevented
by the immunosuppressive cyclosporine A (CsA) (5, 6), indicat-
ing that the pharmacological target of CsA, the mitochondrial
peptidyl-prolyl isomerase F [also known as cyclophilin D (CypD)],
may play an important role in the MPT (7, 8) (see below).
It would be insufficient and inaccurate to assume that the
MPT only results in necrotic cell death. The rupture of the OMM
that occurs during mitochondrial swelling can lead to the release
of mitochondrial proapoptotic factors, such as cytochrome C
(9), apoptosis-inducing factor (AIF) (10), second mitochondria-
derived activator of caspases (SMAC)/direct IAP-binding pro-
tein with low PI (DIABLO) (11), and endonuclease G (EndoG)
(12), and each of these factors can induce proapoptotic activ-
ity in different ways. A role for the MPT in apoptotic cell
death has been supported by several studies. For example, iso-
lated mitochondria exposed to MPT-inducing stimuli undergo
apoptotic-like morphological rearrangements when mixed with
isolated nuclei (13). The MPT inhibitor bongkrekic acid (14)
inhibits cell death, while the MPT inducer atractyloside (9)
renders the cell more susceptible to cell death. Additionally,
the proapoptotic protein B-cell lymphoma (BCL)-associated X
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(Bax) can induce loss of the ∆Ψmt in a CsA-sensitive manner
(15, 16).
Considering that ATP is a critical component in apoptosis, it
is possible that the loss of mitochondrial ATP synthesis (17) as a
result of the MPT would not allow MPT-driven apoptosis. This
possibility is partially supported by studies showing that loss of
the ∆Ψmt does not occur with certain apoptotic stimuli [how-
ever, loss of the ∆Ψmt is not necessarily due to an opening of the
mitochondrial permeability transition pore (mPTP), and mPTP
activity data based on ∆Ψmt measurements must always be vali-
dated by other assays using CsA or other mPTP inhibitors]. Based
on these findings, the MPT may not involve the entire mitochon-
drial network within the cell, and the MPT may only occur at
the level of individual mitochondria (18). These isolated events
could generate a localized and multi-phasic release of mitochon-
drial proapoptotic factors that would eventually result in apoptosis
(19, 20). The cytoplasm, but not the mitochondria, may be the
source of ATP during apoptosis. In this case, an apoptotic event
induced by the MPT could proceed even when loss of the ∆Ψmt
occurs (21).
Additional information about the involvement of the mPTP
in apoptotic and necrotic cell death arrive from two different
studies on transgenic mice lacking the ppif gene, which encodes
mitochondrial CypD (22). Both studies clearly indicate a strategic
role for CypD in MPT-induced necrosis, as cells from ppif−/−
mice appear to be resistant to necrosis induced by both Ca2+
and oxidative stress, as measured by several readouts. The rela-
tionship between the mPTP and apoptosis is less clear. Both
papers clearly show that exposure of isolated mitochondria to
Ca2+ induces cytochrome C release from ppif+/+ cells, while
the same does not occur in ppif−/− cells because this release is
considered one of the master events in the mitochondrial path-
way of apoptosis, which suggests that the mPTP maintains a
role in regulating apoptosis induction (22). Unfortunately, both
papers also show no differences in apoptosis induction between
the two different backgrounds (wt and ko) when induced by stim-
uli such as staurosporine and TNF alpha or during tBid and Bax
overexpression.
The observation of a CypD-dependent cytochrome C release
triggered by Ca2+ in a system that does not display CypD-
dependent apoptosis is paradoxical. The first possible interpre-
tation of the paradox is that mPTP opening is able to induce
cytochrome C release, but the alteration of cellular homeosta-
sis is so rapid and dramatic that necrosis overcomes apopto-
sis. Another possible explanation involves the dose and timing
of the stimuli. For example, in the study of Nakagawa, H2O2
was used as a stimulus to induce cell death. In this case, the
cells answered by engaging necrosis but not apoptosis; how-
ever, it has been extensively reported that hydrogen peroxide
treatment is also able to induce apoptosis [for instance, see in
Ref. (23–26)]. Finally, it should be considered that CypD is not
a structural component of mPTP, but is one of its regulators
(maybe the most investigated of all), and its role in the complex
is to regulate the threshold for Ca2+; however, mPTP opening
is still achievable. Because the mPTP opening mechanism in
response to stimuli such as Bax and Bid is unclear, these proteins
may not require Ca2+ to trigger the MPT and thus would not
require CypD.
Overall, studies on ppif ko mice clearly show that Ca2+ is a trig-
ger for MPT-induced necrosis, but these studies do not exclude
the possibility that MPT is an apoptotic inducer that responds to
other types of triggers.
In conclusion, although the specific type of cell death caused
by the MPT has not been confirmed, the mere existence of the
MPT indicates that mitochondria are master regulators of danger
signals and are capable of transducing life or death signals due to
their interconnection with Ca2+ signaling (27–31).
BACKGROUND ON mPTP STRUCTURE
The mPTP is the putative pore responsible for the MPT, an event
in which the mitochondrial inner membrane, which is highly
impermeable, becomes extremely permeable. The initial model
of the mPTP proposed that the voltage-dependent anion channel
(VDAC) and the adenosine nucleotide transporter (ANT) were
located on the OMM and IMM, respectively and that they were
core components of the pore. These proteins are surrounded by a
series of regulators, including kinases such as hexokinase II (HKII),
creatine kinase (CK), and glycogen synthase kinase 3 β (GSK3β)
(32); the translocator protein (TSPO); CypD; and members of the
Bcl-2 family (22, 33). In particular, the proapoptotic members Bax
and Bcl-2 homologous antagonist killer (Bak) have a dramatic
positive effect on mPTP opening, as confirmed in bax and bak
knockout models (34). The role of these proteins in the regulation
of MPT is likely to depend on their ability to permeate the OMM,
which was partially confirmed in an older study illustrating that
the removal of Bax and Bak led to impaired mitochondrial Ca2+
uptake (35).
The results from VDAC and ANT knockout studies in animal
models, however, have demonstrated that these elements are not
pore-forming components; thus, they have been categorized in the
broad group of activity regulators.
The observation that inorganic phosphate sensitizes the mPTP
suggests that a Pi-binding protein could be associated with the
pore. For a long time, it was thought that this component was
an inorganic phosphate transporter (PiC) based on the observa-
tions that: (i) a non-specific pore is generated in liposomes by
reconstituting the PiC (36), (ii) the PiC interacts with mitochon-
drial CypD and ANT (37), (iii) this interaction is strengthened by
MPT-inducing agents, whereas MPT-blocking compounds dimin-
ish the interaction, and (iv) PiC overexpression induces mito-
chondrial dysfunction and apoptosis (38). These results identi-
fied PiC as a strong candidate for the core-forming element of
the mPTP.
Recent knockdown/knockout experiments performed both
in vitro (39) and in vivo (40, 41) have verified that PiC cannot
be the core component; rather, it serves as an additional regulator.
The sensitivity of the mPTP to inorganic phosphate also drew
our attention to respiratory complex I, NADH:ubiquinone oxi-
doreductase (hereafter referred to as Complex I). It has been
observed that the Complex I inhibitor rotenone is also an inhibitor
of the mPTP, and its effect is dependent on the Pi level (42).
Inhibition of the mPTP by rotenone is apparently linked to the
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activity of Complex I rather than to the production of reactive
oxygen species (ROS) or depletion of pyridine nucleotides (43).
Further, the relationship between Complex I activity and mPTP
inhibition appears to be correlated with structural rearrange-
ments of Complex I (44). This finding led Fontaine’s group
to propose that respiratory Complex I could act as a nega-
tive regulator of mPTP via a direct interaction, which would
depend on the activity of Complex I and the availability of
substrates (42).
Overall, these findings have provided several hypotheses
regarding the regulation of the mPTP; however, a feasible struc-
tural model of the mPTP is still lacking.
The results from a series of studies suggest that mitochondrial
F1/FO ATP synthase (hereafter referred to as ATP synthase) may
be an important component of the mPTP (45–49). Our group
was among the first to demonstrate that the C subunit of mito-
chondrial ATPase is a fundamental regulator of mPTP activity (50,
51). Inhibiting C subunit expression completely blocks the induc-
tion of the MPT by Ca2+ and oxidants, and overexpressing the C
subunit dramatically promotes MPT induction.
Initially, we speculated that the C-ring forms the core of the
mPTP. This speculation was supported by a subsequent study
demonstrating that currents generated by isolated C subunits on
artificial bilayers and in isolated mitochondria are sensitive to
mPTP regulators (52). Despite these findings, no studies have yet
shown that C-rings can exist outside of ATP synthase in vivo or
that they can form “free C-rings” that are capable of generating
currents.
Finally, a recent study by Alavian et al. (53) demonstrated how
the C-ring can generate a non-specific current attributable to
the mPTP. Specifically, these authors found that isolated F1/FO
ATP synthase monomers reconstituted on vesicles can generate
currents when bound to CypD and exposed to Ca2+. Addition-
ally, sub-mitochondrial vesicles enriched in ATP synthase can
also generate a current that is sensitive to Ca2+ and CsA, and
removing the F1 subunit can abolish this sensitivity. Furthermore,
Ca2+-induced mitochondrial swelling can cause the F1 subunit
to partially detach from the FO subunit, and CsA can reverse
this partial detachment. Finally, Alavian et al. further speculated
that the C-ring rearranges during the induction of the MPT such
that its diameter is increased, forming a non-specific channel
(Figure 1).
These findings emphasize the role that ATP synthase, and
especially its C-ring, plays in mPTP formation but do not pro-
vide a clear structural model for the mPTP. First, the precise
conformational rearrangements that promote the generation of
a non-specific current must be determined. Until now, only a
rearrangement of the C-ring, with the potential involvement of the
β subunit, has been proposed. Second, the mechanism underlying
this conformational change in ATP synthase must be elucidated,
and any other subunits that play a role in this rearrangement must
be identified. Finally, the roles played by known components of
the mPTP must be determined. For example, the mechanism by
which targeting of the mPTP regulators affects the sensitivity of
pore opening remains unknown.
Although more studies are required, our understanding of the
mPTP has improved since it was first identified.
FIGURE 1 | Novel structure of the mPTP. In healthy mitochondria, which
are characterized by a dense and interconnected network (top left), the
F1/FO ATP synthase is organized into super-structures with the known
mPTP regulators ANT and PiC. These regulators, in turn, are able to interact
with other mPTP regulators, including HKII, VDAC, TSPO and CK (bottom
left). Induction of MPT results in a reorganization of the F1/FO ATP synthase
structure that allows its C-ring to generate a non-specific current, which
leads to mitochondrial network fragmentation and generation of circular
mitochondria (mitochondrial swelling, top right). These events, which are
usually associated with HKII detachment from the outer mitochondrial
membrane (OMM), are facilitated by interaction with GSK3 and by insertion
of Bax and Bak into the OMM (bottom right).
MOLECULAR ASPECTS OF THE mPTP IN TUMOR
DEVELOPMENT
Evasion of apoptosis is recognized as one of the hallmarks of can-
cer and is required for the development and progression of the
pathology (54). The mPTP can initiate cell death; thus, it may play
a role in cancer.
When considering the potential role of the mPTP in cancer,
investigators often question whether changes in mPTP activity
promote tumor initiation and progression. Several studies on the
mPTP have been conducted in cancer cell lines derived from cer-
vical cancer (50), colon cancer, osteosarcomas (55), leukemia (56),
and many other cancers, and these studies have shown that loss of
the mPTP itself is not sufficient for cancer development. Despite
this observation, several inducers, and other mPTP regulatory
events are inefficient in tumor cells. We will discuss a few of these
cases in this section.
www.frontiersin.org November 2014 | Volume 4 | Article 302 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bonora and Pinton PTP and cancer
ALTERATIONS IN MPT INDUCERS
The best-known MPT inducer is intra-mitochondrial calcium.
Stimuli that elevate the mitochondrial Ca2+ concentration for
a sustained period of time induce the MPT and cell death (57,
58). Ca2+ is provided to mitochondria by the endoplasmic retic-
ulum through specialized domains in which the two organelles
make contact via mitochondria-associated membranes (MAMs)
(27, 28, 59).
Our group and others have demonstrated that cancer cells evade
this type of signaling via several mechanisms. The oncosuppres-
sors promyelocytic leukemia protein (PML) (60) and phosphatase
and tensin homolog (PTEN) (61), in cooperation with protein
phosphatase 2A (PP2A), sustain the Ca2+ transfer between the
ER and mitochondria through the mitochondrial Ca2+ uniporter
(MCU) complex (62) by regulating the phosphorylation state of
the channel responsible for the Ca2+ release: the inositol 3 phos-
phate receptor (IP3R) (63, 64). Loss of these regulators inevitably
reduces the probability of properly initiating the MPT (31). In
contrast, Bcl-2 reduces the Ca2+ content in the ER (65), and the
mitogenic kinase AKT strongly inhibits the IP3R; both of these
factors favor the inhibition of cytotoxic Ca2+ signals (Figure 2).
It appears that tumor progression is sustained by the accumu-
lation of a series of changes in the Ca2+ regulatory machinery that
decrease the cytotoxic Ca2+ signal. In support of this idea, Rimessi
et al. showed that tumor transformation resulting from the onco-
genic activation of the Harvey rat sarcoma viral oncogene homolog
(H-RAS) (66) is accompanied by a progressive reduction in the
amount of intracellular Ca2+ that is transferable to mitochon-
dria. Furthermore, these authors also demonstrated that a con-
trolled increase in the extracellular Ca2+ level causes an increase
in the intracellular Ca2+ level, which impedes H-RAS-induced
transformation (67).
The second most important inducers, which were previously
mentioned, are ROS. The current findings on ROS-induced cell
death and cancer inevitably lead to the following paradox: many
cancer cells have higher basal ROS levels compared with normal
cells, but cancer cells are highly resistant to cell death. One expla-
nation for this paradox is that ROS also promote several hallmarks
of cancer, such as proliferation, invasion, and metastasis [for more
details, see in Ref. (68) and (69)]. Another explanation is that
several cancer cell types have higher levels of antioxidants, which
could inhibit ROS toxicity; specifically, increased levels of superox-
ide dismutase (SOD-2) and thioredoxin reductase 2 (TRX-2) were
observed in mitochondria from cancer tissue samples (70–72).
Furthermore, an elevated ROS level may reduce the mPTP
threshold for Ca2+. Therefore, the decrease in the Ca2+ level
that occurs during cell transformation may allow the ROS level
to increase without alerting the cellular regulatory mechanisms.
Evading these regulatory mechanisms would then allow the tumor
cell to undergo the cancer-promoting changes induced by a high
ROS level.
LEVELS OF mPTP COMPONENTS
Another paradox concerning the involvement of the mPTP in
cancer is related to the expression levels of its components.
Studies in cancer cell lines and tumor models have shown that
different mPTP proteins are overexpressed (73, 74). For example,
FIGURE 2 | Altered mPTP activation in cancer cells. In normal cells, the
transfer of substances between the endoplasmic reticulum and mitochondria
is finely regulated by the phosphorylation status of the IP3Rs. Phosphorylation
can be mediated by the AKT kinase, and proteins are dephosphorylated by
the PP2A phosphatase. This process is regulated by the oncosuppressors
PML and PTEN. In cancer cells, the loss of PML or PTEN allows an increase
in the phosphorylation of IP3R that inhibits Ca2+ transfer between the
endoplasmic reticulum and the mitochondria. Further accumulation of the
oncogenic proteins Bcl-2 and RAS in the endoplasmic reticulum allows
depletion of the Ca2+ store. The reduced amount of transferable Ca2+ prevents
the occurrence of the MPT, despite the increased ROS levels often observed
in cancer cells. Further, the increase in the levels of the ROS detoxifying
enzymes superoxide dismutase-2 (SOD-2) and mitochondrial thioredoxin
reductase (TRX-2) reduces the toxicity of oxidative stress. The region of
contact between the mitochondria and ER, corresponding to the MAMs
structure, is marked with a dashed circle. The yellow circle represents
phosphorylated residues. Green circles represent Ca2+ ions.
the expression levels of VDAC isoforms are significantly higher
in malignant tumor cells (75), and there is a positive correla-
tion between tumorigenesis and the expression level of TSPO,
the ligand of which can induce apoptosis in cancer cells (76,
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77). Furthermore, the adenine nucleotide translocator ANT-2 is
upregulated in renal tumors and transformed hepatocytes (78).
This upregulation, however, may be explained by regulation of the
metabolic status and may not be dependent on the MPT. Analo-
gous to ANT-2 is HKII, the catalyst of the first step of glycolysis.
This enzyme is located on the cytoplasmic side of the mitochondr-
ial outer membrane,where it interacts with other mPTP regulators,
and removing this enzyme from this location causes the mPTP
to open (79, 80). The expression level of HKII is higher in sev-
eral tumors (81–84). However, because of its role in glycolysis,
the upregulation of HKII expression may be linked to the War-
burg effect, which is generally observed in tumors and provides a
metabolic advantage rather than specific resistance to apoptosis.
These findings suggest that the expression levels of the mPTP
components are generally higher in tumors, and this increase is
likely to enhance the probability of mPTP formation and cell death,
in contrast to the reduced sensitivity to apoptosis that is typical
of tumors. The solution to this enigma may be found within the
Bcl-2 family of proteins.
The Bcl-2 family is a well-studied group of proteins involved
in the regulation of apoptosis, necrosis, and autophagy (85, 86).
Within this family, several anti-apoptotic members, such as B-
cell lymphoma-extra large (Bcl-Xl) and myeloid cell leukemia 1
(Mcl-1), are overexpressed in cancer (87). Bcl-Xl has been shown
to negatively regulate mPTP opening by directly interacting with
VDAC (88) at the cytoplasmic side. More recently, the group of
Jonas identified an unexpected mitochondrial-matrix-localized
form of Bcl-Xl that is able to interact with the β subunit of ATP
synthase to promote its synthetase activity and to inhibit mPTP
opening in parallel [Figure 3; (89)].
Although the precise mechanism has not been elucidated, it
has been shown that Mcl-1 plays a role in inhibiting the MPT
(90). Furthermore, it has been proposed that the anti-apoptotic
members Bcl-2, Bcl-Xl, and Mcl-1 interfere with the proapoptotic
interactions induced by Bax and Bak (Figure 3). Specifically, it has
been suggested that Bax and Bak positively regulate the opening
of the mPTP (15, 34, 91). Mutations in the Bax protein have been
identified in gastric and colon cancer (92, 93), and its degrada-
tion is accelerated in prostate cancer (94). Missense mutations in
Bak have been identified in late-stage gastrointestinal cancer (95).
Unlike normal cells, pancreatic cancer cells are unable to properly
increase Bak expression in response to stimuli, which suggests that
the Bax-dependent apoptotic pathway is inhibited (96).
Therefore, it appears that an increase in the mPTP components
in cancer is counteracted by an increase in negative regulators
belonging to the Bcl-2 family or by inactivation of positive regula-
tors belonging to the Bcl-2 family, which may be another strategy
for evading MPT-induced cell death.
CHAPERONE NETWORK AROUND THE mPTP
The gold standard in MPT studies is the use of CsA as a potent
inhibitor of the mPTP. This immunosuppressant is a target of
CypD,a mitochondrial chaperone that is required for proper open-
ing of the mPTP and that confers Ca2+ sensitivity to the complex.
Although its mechanism has not yet been elucidated, it has been
suggested that CypD promotes the rearrangement of the mPTP
subunits to allow for channel formation because it is a chaperone
FIGURE 3 | Protein networks associated with the mPTP in cancer.
Several members of the Bcl-2 family can negatively modulate mPTP
opening via direct interaction. Specially, the proapoptotic proteins Bax and
Bak are sequestered by the anti-apoptotic proteins Bcl-2, Mcl-1, and Bcl-Xl.
Bcl-Xl displays a higher degree of regulation, and its direct interaction with
the β subunit of F1/FO ATP synthase is also considered to inhibit mPTP
opening. A network of chaperones has also been uncovered at the
mitochondrial matrix side. The fundamental mPTP regulator CypD, a
chaperone itself, is able to interact with HSP90, TRAP-1, and HSP60. This
complex appears to inhibit CypD, promoting the closed state of the pore. A
similar situation was observed for DNAJC15, which interacts with CypD and
inhibits the MPT. The question of whether these chaperones are organized
into a unique supramolecular complex remains to be investigated.
protein. Furthermore, other mitochondrial chaperones may also
be involved in a similar mechanism.
Accordingly, heat shock protein 90 (HSP90) was found in a
complex with TNF receptor-associated protein-1 (TRAP-1) and
CypD (97). This complex appears only in tumors and inhibits
apoptosis. Furthermore, the use of mitochondria-targeted ATPase
antagonists is sufficient to block the protection provided by HSP90
and to restore the susceptibility of the cell to apoptosis. Although
mPTP activity was not measured, it was speculated that this
complex is part of a novel cytoprotective pathway that involves
the MPT and is required for tumor growth in vivo (Figure 3).
Another study detected the mitochondrial chaperone heat shock
protein 60 (HSP60) in this same complex (98). This finding
received significant interest because HSP60 is often overexpressed
in tumors (99).
Recently, DnaJ homolog, subfamily C, member 15 (DnaJC15)
has been implicated in control of the MPT. J proteins are chaper-
ones that cooperate with heat shock protein 70 (HSP70) to direct
proteins to specific intracellular locations, such as mitochon-
dria, and DnaJC15 is part of the mitochondrial protein transport
machinery. Ovarian and breast cancer cells from patients exposed
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to chemotherapy displayed reduced levels of DnaJC15 and showed
enhanced resistance to the therapy. This resistance was attributed
to methylation of CpG islands in the gene encoding DnaJC15.
DnaJC15 has not been found to have a role in cell death or
proliferation.
Sinah and D’Silva (100) demonstrated that DnaJC15 regu-
lates mPTP activity by interacting with CypD (Figure 3). These
authors observed that DnaJC15 overexpression induced sponta-
neous MPT, while its downregulation (as observed in cancer)
reduced the sensitivity of mPTP opening when stimulated with
cisplatin.
Thus, the notion is emerging that a complex chaperone net-
work develops in the mitochondria of tumor cells that inhibits
mPTP opening. The existence of this network would at least par-
tially account for the different chaperone levels that are observed
in several types of cancers (101) and would provide a new panel
of pharmacological tools that could selectively target tumors and
reduce the toxicity of the current anticancer strategies (102).
AFFERENT SIGNALING TO THE mPTP
A group of well-known oncogenes and oncosuppressors are able
to modulate Ca2+ homeostasis to regulate induction of the MPT.
Interestingly, some of these factors are able to localize to MAMs,
potentially to increase the selectivity and efficiency of their regula-
tory effect. This is the case for AKT (103) and two oncosuppressors,
PML (63), and PTEN (64). At these sites, AKT, PML, and PTEN
appear to exist in a complex that interacts with and determines
the phosphorylation status of the IP3R, which affects its channel
activity (Figure 2). This model has received a significant amount of
interest because AKT and PTEN are both members (with opposite
functions) of the PI3K pathway, which is one the most well-studied
survival signaling pathways and plays a critical role in resistance
to anticancer therapies (104–106).
AKT may affect mPTP activity through another mechanism
that is not directly related to Ca2+ signaling. AKT can induce
the phosphorylation of GSK3β, which results in its inactivation.
GSK3β kinase has a significant stimulatory effect on the mPTP. Its
inactivation by AKT strengthens the association between HKII and
VDAC, causing inhibition of mPTP function and an increase in cell
survival (107). Alterations in GSK3β have been found in several
cancer types [for details, see in Ref. (108)]; furthermore, GSK3β is
of significant interest because it could act as a convergence factor
that allows survival signaling pathways to interact with the mPTP.
In addition to the growth signals stimulated by AKT, the wing-
less integrated human homolog (WNT), protein kinase C (PKC),
and extracellular signal-regulated kinase (ERK) pathways can also
regulate GSK3β phosphorylation, which potentially connects the
MPT to signals stimulated by growth factors, ligands of G protein-
coupled receptors, and the extracellular matrix [Figure 4; (109,
110)].
To further emphasize the potential role of GSK3β in regulating
the mPTP in cancers, the activation of GSK3β causes the release
of HKII from the OMM. The use of synthetic inhibitors showed
that this event can induce cell death in cancer cell lines (79).
The epsilon isoform of PKC (PKCε) has been proposed to
have a mechanism of action that is independent of GSK3β. First,
PKCε was proposed to form a complex with VDAC1–HKII–ANT,
FIGURE 4 |The prosurvival pathway converges on the mPTP. GSK3β is
a negative regulator of the mPTP, and its activity is inhibited by
phosphorylation by AKT and PKCs. GSK3β functions as a hub for different
survival signals at the interface with mPTP. In addition, PKCε can stabilize
the interaction with HKII by phosphorylating VDAC.
thereby inducing VDAC1 phosphorylation and the consequent
inhibition of mPTP activity (Figure 4). However, PKCε was also
shown to reduce the Ca2+ content in the sarcoplasmic reticulum
during preconditioning of cardiac tissue. This is likely to reduce
the probability of mPTP induction during ischemia/reperfusion,
conferring a mechanism for preconditioning-mediated cardiopro-
tection (111). The question of whether this event could be relevant
in the tumor environment has yet to be addressed.
mTOR, a negative regulator of autophagy, functions down-
stream of the AKT pathway. Targeting mTOR inhibits the mPTP
to a similar extent as activating AKT and inactivating GSK3β, and
inhibition of mTOR enhances the binding of HKII to VDAC (112).
Thus, kinase cascades that are significantly activated in can-
cers can maintain HKII bound to the mitochondrial surface via
inhibiting GSK3, thus keeping the mPTP closed. These events may
contribute to the anti-apoptotic phenotype of tumor cells and to
the development of resistance to therapies. In contrast, strategies
directed at activating GSK3 may increase the sensitivity of mPTP
opening and increase the probability of tumor regression (113).
mPTP AND THE WARBURG EFFECT
Mitochondrial permeability transition-driven cell death is closely
associated with the hypoxia-induced ischemia that occurs in nor-
mal tissue as well as the consequent reperfusion injury. The current
model proposes that during ischemia, the accumulation of lac-
tate resulting from oxygen deprivation leads to a decrease in the
pH and activation of the Na+/H+ exchanger, which is required
to buffer the cytoplasmic pH. Accumulation of Na+ is then pre-
vented via the action of the Na+/Ca2+ exchanger, which increases
the cytosolic Ca2+ concentration ([Ca2+]c). The accumulation of
cytoplasmic Ca2+ is further increased by a reduction in the activity
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of the Ca2+ pumps located on the sarcoplasmic reticulum and sar-
colemma because of the loss of ATP. Furthermore, the sustained
loss of ATP leads to temporary accumulation of ADP, which is
converted to adenine monophosphate (AMP) and adenosine and
results in the accumulation of Pi. It has been shown that Pi induces
the MPT. During ischemia, cells accumulate MPT inducers (Ca2+,
Pi) and lose one of the most important MPT inhibitors, ADP
(114). The most detrimental effects, however, are not observed
until reperfusion, when a significant amount of ROS is produced
that definitively and dramatically induces the MPT and necrosis.
Based on these findings, induction of the MPT has been monitored
during myocardial (115) and brain reperfusion injury (116).
The unregulated growth of a solid tumor mass generates a
hypoxic environment. This condition is not irreversible; rather,
it is intermittent and characterized by cycles of hypoxia and re-
oxygenation (117). This condition should induce the same mecha-
nism of mPTP opening that has been observed in the myocardium
and brain and should thus reduce tumor size. These events, how-
ever, have not been observed in actual solid cancers, which suggests
that a different protection mechanism is involved in these tumors.
One potential protection mechanism is related to the Warburg
effect, which is the dramatic increase in glucose uptake and lactate
fermentation observed in tumor masses (118, 119). Solid tumors
display an extraordinary capacity for glucose uptake, which is
a property that is exploited for the diagnosis of solid tumors.
Glucose is converted to pyruvate, which is further reduced to
lactate to complete the lactate fermentation process. These reac-
tions occur even in the presence of functional mitochondria; thus,
their purpose and significance remains controversial (120, 121).
Nonetheless, the findings reported by Warburg have been con-
firmed by other groups and result in two main consequences for
the MPT. First, the increase in glucose uptake allows for the con-
tinued synthesis of ATP through glycolysis, which impedes the
depletion of adenine nucleotides and Pi accumulation that were
described in the previous model. Second, the accumulation of
lactate lowers the pH, thus inhibiting the mPTP. This finding sug-
gests that the Warburg effect alone may result in mPTP inhibition
(Figure 5).
A more direct potential mechanism involves hypoxia-inducible
factor 1α (HIF1α). HIF1α is a heterodimeric protein that acts
as an oxygen-level sensor because its degradation is prevented
by ROS accumulation. Additionally, HIF1α activates the tran-
scription of genes that favor glycolysis and lactate fermentation
while suppressing mitochondrial respiration [for further review,
see in Ref. (122)]. The reduction in the mitochondrial potential
resulting from a reduction in mitochondrial respiration inhibits
Ca2+ uptake and the significant increase in ROS. Both of these
events activate the mPTP (see above); however, because of its
ability to stabilize HKII, the effect of HIF1α on the MPT is
even more direct (123). Gwak and colleagues demonstrated that
hypoxia promotes the expression of HKII, which inhibits the
mPTP through HIF1α (Figure 5). Consistent with this finding, the
selective inhibition of HKII induces apoptotic cell death, which
is analogous to the results observed when HKII is induced to
detach from mitochondria (79). Unfortunately, the authors did
not directly demonstrate the involvement of the mPTP in this
mechanism.
FIGURE 5 | Metabolic alterations in the cancer environment affect
mPTP activity. The dramatic increase in glucose uptake due to the
Warburg effect boosts glycolysis, sustaining the ATP/ADP exchange due to
metabolic reactions. Further, the high levels of pyruvate promote lactate
production and cytosol acidification. ATP, ADP, and a low pH can
synergistically exert strong inhibitory effects on the MPT. In addition, the
hypoxic environment generated in solid tumors stabilizes the HIF1α
transcription factor and allows the expression of genes involved in buffering
of ROS. Further, HKII is also upregulated, and its binding to the mPTP is
enhanced, thus stabilizing the closed state of the pore.
Older biochemical data indicate that when HKII is bound to
the mPTP, glucose can induce mPTP inhibition; on the other
hand, glucose-6-phosphate, which is the product of HKII, induces
detachment of HKII from mitochondria (124). Because HIF1α
can promote both glucose uptake (by elevating the levels of the
glucose transporter GLUT1) and its conversion through glycolytic
flux, it can be speculated that elevation of HIF1α in cancer will
further inhibit mPTP activity by increasing the levels of glucose
(to be considered as an inhibitor of mPTP) but can also impede
the accumulation of glucose 6-phosphate (which can serve as an
mPTP inducer) through the regulation of glycolytic enzymes and
inhibition of pyruvate dehydrogenase (PDH).
Finally, the reduced oxygen levels in the tumor environment
should decrease the activity of the respiratory chain and Com-
plex I. We previously mentioned that Complex I inhibition can
result in mPTP inhibition; thus, it can be postulated that hypoxia
may impair mPTP activity via its effects on Complex I. However,
it should be noted that the role of Complex I activity in cancer is
controversial. Mutations in mitochondrial DNA that impair Com-
plex I function reveal that the activity of Complex I is essential
for stabilizing HIF1α and for generating the Warburg phenotype
(125). Concurrently, another group observed that overexpression
of Ndi1 (a subunit of yeast Complex I with dehydrogenase activ-
ity) favors mitochondrial metabolism in breast cancer cells and
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reduces breast cancer tumor formation and metastasis (126). Both
studies accounted for the effect on the NADH/NAD+ ratio: the
first study indicated that a decrease in the NADH/NAD+ ratio
could lead to a decrease in α ketoglutarate (required for the sta-
bilization of HIF1α), and the second study showed that NAD+
could regulate mTORC1 and autophagy, leading to inhibition of
tumor growth. It should be noted that in several types of cancer,
mutations in mitochondrial DNA have been reported (127–130),
and the ability of these mutations to increase ROS seems to confer
an advantage to tumors, especially during metastasis formation
(131).
Overall, the findings from previous studies suggest that inhibi-
tion of the mPTP plays a role in the resistance of solid tumors to
hypoxic conditions.
CONCLUDING REMARKS
Because defects in the cell death pathway are considered a hall-
mark of tumor initiation and progression, the MPT is a potential
target for rescuing oncogenic defects. In-depth studies on mPTP
activity have been conducted to identify the factors that inhibit the
activation of cell death pathways.
Functional mPTPs can be found in cancer cell lines, indicating
that mPTPs are not completely inhibited in cancer. Furthermore,
several structural elements of the pore are overexpressed and not
downregulated in these cell lines. These findings are most likely the
result of the paradoxical nature of the mPTP. More recent studies
have proposed the existence of an “evolved aberrant conforma-
tion” of extremely efficient components that are indispensable for
mitochondrial physiology (such as ion and solute transporters as
well as chaperones).
Nevertheless, several mPTP regulatory mechanisms are
impaired in tumors compared with the surrounding tissues. These
alterations can be categorized as: (i) alterations in the concentra-
tions of mPTP inducers (i.e., Ca2+), (ii) promotion or inhibition
of regulators that interact directly with the mPTP (i.e., chaperone
networks), (iii) desensitization through kinase signaling pathways,
and (iv) inhibition mediated by metabolic changes. All of these
mechanisms do not necessarily occur in the same tumor type;
however, they are not necessarily independent and can integrate
with each other.
Interestingly, the establishment of this variety of integrated
mPTP inhibition mechanisms may be the result of an evolution-
ary process. Opening of the mPTP may have acted as a selection
pressure that only permitted the proliferation of cells capable of
evading the MPT induction mechanism.
It may be possible to generate such selection pressure via
autophagy, the process by which cytoplasmic constituents are
sequestered into double-membrane vesicles called autophago-
somes and selectively degraded by fusion of the autophagosomes
with lysosomes. Opening of the mPTP can lead to loss of Ψm,
with subsequent swelling of the mitochondrial matrix.
It has been reported that damaged and depolarized mito-
chondria are sequestered into autophagic vacuoles in a selec-
tive form of autophagy called “mitophagy” (132, 133). In 1997,
Lemaster’s group initially proposed that the MPT could mediate
the depolarization required for selective degradation of mito-
chondria through autophagy (134). These researchers observed
spontaneous mitochondrial depolarization preceding organelle
fusion with lysosomes (presumably through autophagosome and
autophagolysosome formation), and the frequency of these events
increased dramatically when autophagy was induced by serum
starvation.
Strong support for this hypothesis was provided in a more
recent study in which the authors showed that mitochondr-
ial depolarization (induced by serum starvation) was dramat-
ically inhibited by administration of the CypD inhibitor CsA.
CsA administration, in addition to knocking down CypD, pre-
vents mitochondrial sequestration into autophagosomes, indicat-
ing that serum starvation leads to mPTP opening that in turn
drives selective mitochondrial degradation (here, the MPT was
detected as mitochondrial depolarization, which, as previously
stated, should be used carefully and in combination with the
appropriate controls).
The connection between MPT and autophagy in cancer is less
clear, mostly because knowledge regarding autophagy and cancer
is scarce, and the data are controversial.
In fact, several autophagy genes have been found to be compro-
mised in several types of cancers, and overexpression of some of
these genes results in autophagy activation and growth inhibition
(135–137). However, it has also been observed that nutritional
stress (low availability of nutrients, oxygen, and mitogens) in the
tumor environment leads to autophagy activation that in turn
promotes tumor survival. Despite this finding, different studies
have indicated that dysfunctional mitochondria accumulate in
cancer, apparently due to dysfunctional mitophagy, which facili-
tates the accumulation of ROS (see above) and favors the metabolic
reprograming that occurs in cancer (138–141).
Considering the previous findings regarding MPT and
mitophagy, it could be speculated that an increase in the mPTP
threshold occurs early in tumor transformation, impeding the
spontaneous depolarization that should “mark” stressed mito-
chondria for selective degradation. This would lead to accumula-
tion of mitochondria and a continuation of ROS generation, which
in turn triggers the proliferative pathway for tumor formation.
Unfortunately, no studies have reported findings that are suffi-
cient to validate this hypothesis; however, some studies on cancer
stem cells (CSCs) have provided clear evidence. CSCs are cells
that are able to undergo self-renewal and are committed to a
cancer cell lineage, thus generating a tumor. The existence of
these cells was initially hypothesized as part of a model that
would explain the origins of tumor heterogeneity; however, their
existence has finally been confirmed in several types of cancer
(142–145), and they are now intensively being investigated. In a
recent paper by Vega-Naredo and co-workers, several mitochon-
drial features were investigated during the differentiation of a cell
line derived from a teratocarcinoma called P19 (146). This embry-
onic carcinoma cell line is pluripotent and can be induced in
immortalized endodermal or mesodermal cells by retinoic acid.
In this study, the authors observed that during the differentia-
tion process, mPTPs switch from a more opened state to a more
closed state. Although the effect of retinoic acid on mPTPs was not
addressed, this study supports the possibility that cancer cells have
evolved mechanisms to escape mPTP opening by desensitizing
mPTPs.
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In addition, several strategies designed to rescue mPTP activity
have shown significant success [for extensive reviews, see in Ref.
(74, 147, 148)].
Overall, a growing body of evidence suggests that inhibition of
the mPTP may be a protective mechanism for cancer cell survival
and proliferation and that targeting the mPTP may be a promising
strategy for improving anticancer therapies.
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